The hospital acquired infections testing kits market reached a value of nearly $3783.5 million in 2021, having increased at a compound annual growth rate (CAGR) of 12.7% since 2016. The market is expected to grow from $3783.5 million in 2021 to $5357.4 million in 2026 at a rate of 7.2%. The market is then expected to grow at a CAGR of 8.3% from 2025 and reach $7966.0 million in 2031.
Growth in the historic period resulted from an increase in increased hospital-acquired infections (HAIs), increased aging population and increased number of surgeries. Going forward, the increase in chronic diseases, a rise in healthcare expenditure and increasing government support will drive the growth. Factors that could hinder the growth of the hospital acquired infections testing kits market in the future include a rise in interest rates and lack of healthcare infrastructure.
The global hospital acquired infections testing kits market is fragmented, with a large number of small players. The top ten competitors in the market made up to 13.63% of the total market in 2021. Becton, Dickinson and Company was the largest competitor with 2.76% share of the market, followed by Abbott Laboratories with 2.44%, Cepheid with 2.11%, F. Hoffmann-La Roche Ltd. with 1.95%, Hologic, Inc. with 1.68%, STERIS plc with 1.55%, QIAGEN with 0.34%, Meridian Bioscience Inc. with 0.30%, bioMérieux SA with 0.26%, and Metall Zug (Belimed Group) with 0.24%.
Player-adopted strategies in the hospital acquired infections testing kits market include launching new products, increasing geographic reach, decentralizing point-of-care testing and acquiring companies with innovative near-patient, and acute care diagnostic testing.
Request Research Sample with Latest Industry Insights (270+ Pages Report): https://altusmarketresearch.com/reports/sample/43265
The hospital acquired infections testing kits market is segmented by product into consumables and reagents and instruments. The consumables & reagents market was the largest segment of the hospital acquired infections testing kits market segmented by product, accounting for 59.6% of the total in 2021. Going forward, the instruments market is expected to be the fastest growing segment in the hospital acquired infections testing kits market segmented by product, at a CAGR of 7.5% during 2021-2026.
The hospital acquired infections testing kits market is by test type into pneumonia infection, urinary tract infection, blood stream associated infection, surgical site infection, MRSA infection and others. The urinary tract infection market was the largest segment of the hospital acquired infections testing kits market segmented by test type, accounting for 40.2% of the total in 2021. Going forward, the pneumonia infection segment is expected to be the fastest growing segment in the hospital acquired infections testing kits market segmented by test type, at a CAGR of 7.7% during 2021-2026.
The hospital acquired infections testing kits market is segmented by application into drug-resistance testing, disease testing. The disease testing market was the largest segment of the hospital acquired infections testing kits market segmented by application, accounting for 66.4% of the total in 2021. Going forward, the drug-resistance testing segment is expected to be the fastest growing segment in the hospital acquired infections testing kits market segmented by application, at a CAGR of 8.0% during 2021-2026.
The hospital acquired infections testing kits market is segmented by pathogen type into viral, bacterial, fungal. The viral market was the largest segment of the hospital acquired infections testing kits market segmented by pathogen type, accounting for 47.2% of the total in 2021. Going forward, the fungal segment is expected to be the fastest growing segment in the hospital acquired infections testing kits market segmented by pathogen type, at a CAGR of 7.4% during 2021-2026.
North America was the largest region in the hospital acquired infections testing kits market, accounting for 36.2% of the total in 2021. It was followed by Asia-Pacific, and then the other regions. Going forward, the fastest-growing regions in the hospital acquired infections testing kits market will be South America, Africa and, Middle East where growth will be at CAGRs of 9.3%, 8.8% and 8.8% respectively. These will be followed by Asia Pacific, and Western Europe, where the markets are expected to grow at CAGRs of 8.5% and 6.6% respectively.
The unprecedented outbreak of coronavirus has caused a surge in demand for hospital acquired infections testing kits, due to the rise in hospital acquired infections during the pandemic. The pandemic has raised enormous quality of care concerns in hospitals, due to the rising number of patients during COVID-19 and the change in staffing numbers. Multiple hospitals have experienced an increase in staffing levels, with traveling nurses reporting that these nurses were unfamiliar with hospital’s infection control processes. Such circumstances made it difficult for hospitals to maintain patient safety and quality of care. According to a U.S. Department of Health and Human Services report, one hospital in the US experienced an increase in central line infections during COVID-19, including life-threatening infections. COVID-19 patients usually experienced a lengthy stay in hospitals, making them more prone to hospital acquired infections.
The top opportunities in the hospital acquired infections testing kits market segmented by product will arise in the consumables and reagents segment, which will gain $905.9 million of global annual sales by 2026. The top opportunities in the hospital acquired infections testing kits market segmented by test type will arise in the urinary tract infection segment, which will gain $645.9 million of global annual sales by 2026. The top opportunities in the hospital acquired infections testing kits market segmented by application will arise in the disease testing segment, which will gain $980.0 million of global annual sales by 2026. The top opportunities in the hospital acquired infections testing kits market segmented by pathogen type will arise in the bacterial segment, which will gain $727.2 million of global annual sales by 2026. The hospital acquired infections testing kits market size will gain the most in the USA at $450.1 million.
Market-trend-based strategies for the hospital acquired infections testing kits market include collaborating with artificial Intelligence companies, leveraging aid from government, incorporating big data into their market analysis and partnering with other players in the market.
To take advantage of the opportunities, Altus Market Research recommends the hospital acquired infections testing kits companies to use artificial intelligence, focus on use of big data, consider strategic partnerships and acquisitions, continue to expand in developed markets, set up authorized distributors and sales representatives, focus on competitive pricing, promote products and services via social media platforms and target doctors and pharmacists to spread awareness.